Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic
Authors:
- Judith Bammert AdamsJAJudith Bammert Adams
- Robert E. PykeRPRobert E. Pyke
- Jack CookJCJack Cook
- Pam ZacchariasPZPam Zaccharias
- Dane WingersonDWDane Wingerson
- Peter P. Roy-ByrnePRPeter P. Roy-Byrne
- 1 September 1996
- journal article
- clinical trial
- Published by Elsevier in Biological Psychiatry
- Vol. 40 (6) , 550-552
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- A Double-Blind, Placebo-Controlled Study of a CCK-B Receptor Antagonist, CI-988, in Patients With Generalized Anxiety DisorderJournal of Clinical Psychopharmacology, 1995
- The Panicogenic Effects of Cholecystokinin-Tetrapeptide Are Antagonized by L-365,260, a Central Cholecystokinin Receptor Antagonist, in Patients With Panic DisorderArchives of General Psychiatry, 1994
- The behavioural properties of CI‐988, a selective cholecystokininB receptor antagonistBritish Journal of Pharmacology, 1991
- Enhanced Sensitivity to Cholecystokinin Tetrapeptide in Panic DisorderArchives of General Psychiatry, 1991
- Evaluation of the effects of PD 134308 (CI-988), A CCK-B antagonist, on the punished responding of squirrel monkeysNeuropeptides, 1991
- The Diagnostic Utility of Lactate Sensitivity in Panic DisorderArchives of General Psychiatry, 1990
- Cognitive determinants of lactate-induced anxietyBehaviour Research and Therapy, 1986